« Back
Home /
L-NAME (hydrochloride)

L-NAME (hydrochloride)

Item no.	HY-18729A-100mg
Manufacturer	MedChem Express
CASRN	51298-62-5
Amount	100 mg
Quantity options	100 mg 10 g 10 mM/1 mL 1 g 25 g 500 mg 50 g 5 g
Category	Metabolism Cholesterol & Lipid Metabolism Enzymes Other Fatty Acid Enzymes Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.89
Citations	[1]Pfeiffer S, et al. Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement forbioactivation to the free acid, NG-nitro-L-arginine. Br J Pharmacol. 1996 Jul;118(6):1433-40.\|[2]Kopincová J, et al. L-NAME in the cardiovascular system - nitric oxide synthase activator? Pharmacol Rep. 2012;64(3):511-20.\|[3]Lo HC, et al. The Nitric Oxide Synthase Inhibitor NG-Nitro-L-Arginine Methyl Ester Diminishes the Immunomodulatory Effects of Parental Arginine in Rats with Subacute Peritonitis. PLoSOne. 2016 Mar 23;11(3):e0151973.\|[4]Luo H, et al. Effect of nitric oxide synthase inhibitor L-NAME on fear extinction in rats: a task-dependent effect. Neurosci Lett. 2014 Jun 20;572:13-8.\|[5]Ocsan RJ, et al. Chronic NG-nitro-l-arginine methyl ester (L-NAME) administration in C57BL/6J mice induces a sustained decrease in c-kit positive cells during development of cardiac hypertrophy. J Physiol Pharmacol. 2013 Dec;64(6):727-36.\|[6]V A Peotta, et al. Cardiovascular neural reflexes in L-NAME-induced hypertension in mice. Hypertension. 2001, 38, 3.\|[7]Xiaofei Li, et al. Fucoidan from Undaria pinnatifida prevents vascular dysfunction through PI3K/Akt/eNOS-dependent mechanisms in the l-NAME-induced hypertensive rat model. Food Funct. 2016, 7, 5.\|[8]de Alwis N, et al. The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health. Life Sci Alliance. 2022 Aug 5;5(12):e202201517. Adv Sci (Weinh). 2024 Jun;11(21):e2309002. Aging Cell. 2025 Feb 6:e14502. Aging Cell. 2025 Sep 29:e70222. Am J Physiol Cell Physiol. 2025 Oct 30. Arterioscler Thromb Vasc Biol. 2020 Jul;40(7):1705-1721. Bioengineered. 2022 Jan;13(1):1320-1334. Biol Direct. 2024 Nov 26;19(1):121. Biomed Pharmacother. 2019 Jul:115:108934. Biomed Pharmacother. 2023 May:161:114484. Biomed Res Int. 2021 May 14:2021:5565748. bioRxiv. 2023 Dec 4. bioRxiv. 2023 Nov 1. bioRxiv. 2025 May 06. BMC Nephrol. 2024 Jul 15;25(1):226. Bosn J Basic Med Sci. 2017 May 20;17(2):132-137. Brain Dev. 2025 Jul 1;47(4):104388. Cancer Metab. 2024 May 17;12(1):14. Cancer Res. 2024 Jun 14;84(12):1963-1977. Cardiovasc Diabetol. 2024 May 9;23(1):164. Cell Commun Signal. 2021 Mar 18;19(1):35. Chem Biol Interact. 2025 May 28:111577. Clin Epigenetics. 2025 Nov 19;17(1):195. Clin Exp Pharmacol Physiol. 2025 Nov;52(11):e70081. Commun Biol. 2025 Nov 25;8(1):1682. Evid Based Complement Alternat Med. 2020 Mar 10;2020:3524641. Exp Anim. 2025 Oct 30. Exp Ther Med. 2018 Aug;16(2):1079-1086. FASEB J. 2024 Jul 31;38(14):e23844. FASEB J. 2025 Jul 31;39(14):e70817. FASEB J. 2025 Jun 15;39(11):e70697. Free Radic Biol Med. 2024 Sep 13:S0891-5849(24)00659-2. Free Radic Biol Med. 2025 Jul:234:72-85. Front Cardiovasc Med. 2021 Apr 13:8:654254. Front Med. 2021 Apr 13:8:634882. Hum Gene Ther. 2023 Jan;34(1-2):42-55. Insect Mol Biol. 2024 Jun;33(3):206-217. Int Immunopharmacol. 2024 Jan 25:127:111313. Int Immunopharmacol. 2024 Nov 13;143(Pt 3):113617. Int J Immunopathol Pharmacol. 2022 Jan-Dec:36:3946320221111117. Int J Med Sci. 2025 Jan 21;22(4):920-932. Int J Mol Med. 2024 Aug;54(2):67. Int J Mol Sci. 2023 Mar 7;24(6):5111. J Cardiovasc Transl Res. 2024 Dec;17(6):1415-1426. J Cell Mol Med. 2024 Apr;28(8):1-11. J Ethnopharmacol. 2022 Oct 5:296:115476. J Extracell Vesicles. 2023 May;12(5):e12328. J Nanobiotechnology. 2025 Aug 26;23(1):590. JCI Insight. 2021 Sep 22;6(18):e133690. Mediators Inflamm. 2019 Oct 7;2019:6168340. Mediators Inflamm. 2020 Oct 24;2020:1649453. Microorganisms. 2024 Dec 2;12(12):2483. Microvasc Res. 2023 Jul:148:104531. Mol Cell Probes. 2023 Feb:67:101896. Nutrients. 2022 Nov 25;14(23):5025. PeerJ. 2023 May 25:11:e15407. Peptides. 2024 Dec 5:183:171333. Phytomedicine. 2022 Sep:104:154242. Placenta. 2021 Mar:106:30-39. Placenta. 2022 Jan:117:95-108. Res Sq. 2025 Nov 12. Research Square Preprint. 2021 Feb. Research Square Preprint. 2022 May. Research Square Preprint. 2023 May 30. Sci Rep. 2025 Oct 31;15(1):38208. Sex Med. 2025 Aug 6;13(4):qfaf059. Signal Transduct Target Ther. 2025 May 28;10(1):167. Toxicol Appl Pharmacol. 2019 Mar 1:366:83-95. University of Jena. 2023 Dec. Vet Microbiol. 2022 Sep:272:109514. Biomed Pharmacother. 2020 Aug;128:110240. Cell Tissue Res. 2022 Apr;388(1):181-194.
Smiles	N[C@@H](CCCNC(N[N+]([O-])=O)=N)C(OC)=O.[H]Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	NG-Nitroarginine methyl ester hydrochloride
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Category	Reference compound / Active compounds
Manufacturer - Targets	NO Synthase
Manufacturer - HS Code	H302, H315, H319, H335
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, sealed storage, away from moisture)
Molecular Weight	269.69
Product Description	L-NAME hydrochloride inhibits NOS with an IC50 of 70 μM. L-NAME is a precursor to NOS inhibitor L-NOARG which has an IC50 value of 1.4 μM.
Manufacturer - Research Area	Cancer
Solubility	H2O : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Immunology/Inflammation
Clinical information	Phase 2
UNSPSC Code	12352211
Precautionary	H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.